Glimepirida Viatris

Glimepirida Viatris is a prescription oral medication that contains the active ingredient glimepiride, a sulfonylurea class drug used to manage blood glucose levels in adults with type 2 diabetes mellitus. It is marketed in the European Union and is taken by mouth. The product’s specific strength and dosage form are not disclosed in the available information.

Glimepirida Viatris is indicated for the treatment of type 2 diabetes mellitus as part of a comprehensive diabetes management plan. It may be used alone or in combination with other antidiabetic agents.

- Improves glycemic control when diet and exercise alone are insufficient. - Can be combined with metformin, DPP‑4 inhibitors, or SGLT2 inhibitors for enhanced effect. - May be prescribed for patients who have not achieved target HbA1c with other oral agents. - Used in adults when a sulfonylurea is appropriate based on clinical judgment. - Supports long‑term management of hyperglycemia in type 2 diabetes.

Glimepirida Viatris may cause a range of side effects, most of which are mild and transient. Serious adverse reactions are less common but require prompt medical attention.

Common: - Hypoglycemia (low blood sugar) - Nausea or abdominal discomfort - Headache - Dizziness or light‑headedness - Weight gain - Skin rash or itching

Serious: - Severe hypoglycemia leading to loss of consciousness - Allergic reactions such as angioedema or Stevens‑Johnson syndrome - Hepatic dysfunction (elevated liver enzymes) - Hematologic abnormalities (e.g., leukopenia, thrombocytopenia)

Before starting Glimepirida Viatris, certain precautions should be considered to ensure safe use.

- Assess renal and hepatic function; dose adjustments may be needed. - Use caution in elderly patients who are more prone to hypoglycemia. - Monitor blood glucose regularly, especially when initiating therapy or changing dose. - Avoid use during pregnancy and lactation unless benefits outweigh risks. - Discontinue if signs of severe hypoglycemia or allergic reaction occur. - Inform healthcare providers of all concurrent medications and medical conditions.

Glimepirida Viatris can interact with several drug classes, affecting its efficacy or safety profile.

Avoid: - Other sulfonylureas or insulin, which can increase risk of severe hypoglycemia. - Strong CYP2C9 inhibitors (e.g., fluconazole, amiodarone) that may raise glimepiride levels. - MAO‑B inhibitors, which may potentiate hypoglycemic effects.

Use with caution: - Beta‑blockers, which can mask hypoglycemia symptoms. - Thiazide diuretics, which may raise blood glucose. - Antifungal agents like itraconazole that moderately inhibit metabolism. - NSAIDs, which can affect renal function and glucose control.